Table 3 Univariate and multivariable analyses of prognostic factors
Factor | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
P value | HR (95% CI) | P value | HR (95% CI) | |
Treatment | ||||
 RP |  | Ref. |  | Ref. |
 LDR | 0.004 | 0.53 (0.35–0.81) | 0.067 | 0.50 (0.24–1.05) |
Age, years | ||||
  < 70 |  | Ref. |  | Ref. |
  ≥ 70 | 0.001 | 0.50 (0.33–0.76) | 0.29 | 0.72 (0.40–1.31) |
Clinical T stage | ||||
 T1c, T2a |  | Ref. |  | Ref. |
 T2b, T2c | 0.005 | 1.99 (1.23–3.23) | 0.43 | 1.29 (0.69–2.39) |
iPSA, ng/ml | ||||
  ≤ 10 |  | Ref. | – | – |
 10.1–20 | 0.15 | 0.73 (0.47–1.12) | – | – |
Gleason score | ||||
 6(3 + 3) |  | Ref. | – | – |
 7(3 + 4) | 0.52 | 0.86 (0.53–1.38) | – | – |
 7(4 + 3) | 0.095 | 0.62 (0.35–1.09) | – | – |
Prostate volume, ml | ||||
  ≤ 30 |  | Ref. |  | Ref. |
  > 30 |  < 0.001 | 0.35 (0.22–0.56) |  < 0.001 | 0.33 (0.18–0.60) |
PPBC | ||||
  ≤ 50% |  | Ref. |  | Ref. |
  > 50% |  < 0.001 | 2.83 (1.85–4.33) |  < 0.001 | 1.19 (1.71–5.95) |
Duration ADT, months | ||||
 0 |  | Ref. |  |  |
 1–6 | 0.254 | 0.72 (0.65–1.29) | 0.106 | 2.61 (0.87–4.13) |
  > 6 | 0.177 | 0.59 (0.51–0.71) | 0.426 | 0.63 (0.62–3.13) |
Surgical margin status | ||||
 Positive |  < 0.001 | 2.51 (1.54–3.78) |  < 0.001 | 2.64 (1.20–4.18) |
 Negative |  | Ref. |  |  |
Risk level | ||||
 Favorable risk | 0.492 | 1.23 (0.68–2.21) | 0.944 | 0.97 (0.39–2.41) |
 Unfavorable risk | ||||